Pharmacokinetics
BLOOD
Blood samples were collected at predetermined time points. Isatuximab plasma concentrations were determined with a validated ELISA method (lower limit of quantification, 0.500 ng/mL). Lenalidomide and bortezomib plasma concentrations were determined using validated LC-MS/MS methods (lower limits of quantification, 1.00 ng/mL and 0.500 ng/mL, respectively). PK parameters were calculated based on a non-compartmental analysis (NCA) from the isatuximab, bortezomib, and lenalidomide plasma concentrations obtained after the first and repeated administrations.